Prestige Consumer Healthcare Files 10-Q for Q3 2024

TL;DR

**PBH Q3 2024 10-Q filed. Financials out.**

AI Summary

Prestige Consumer Healthcare Inc. filed its 10-Q for the period ending December 31, 2024. The company reported financial results for the third quarter and the first nine months of its fiscal year. Specific financial figures for revenue, net income, and other key metrics for these periods are detailed within the filing.

Why It Matters

This filing provides investors with an update on Prestige Consumer Healthcare's financial performance and operational status, crucial for understanding the company's current health and future prospects.

Risk Assessment

Risk Level: medium — 10-Q filings are standard financial reports, but the specific details within can reveal significant financial performance or strategic shifts that may impact risk.

Key Numbers

• 2024-12-31 — Fiscal Year End (Reporting period end date)
• 2025-02-06 — Filing Date (Date the 10-Q was submitted)

Key Players & Entities

• Prestige Consumer Healthcare Inc. (company) — Filer of the 10-Q
• 2024-12-31 (date) — End of reporting period
• 2025-02-06 (date) — Filing date
• Prestige Brands Holdings, Inc. (company) — Former company name
• Prestige Household Brands, Inc. (company) — Former company name

FAQ

Key Financial Figures

• $0.01 — ich registered Common stock, par value $0.01 per share PBH New York Stock Exchange

Filing Documents

• pbh-20241231.htm (10-Q) — 1462KB
• exhibit3112024-12x31.htm (EX-31.1) — 11KB
• exhibit3122024-12x31.htm (EX-31.2) — 11KB
• exhibit3212024-12x31.htm (EX-32.1) — 5KB
• exhibit3222024-12x31.htm (EX-32.2) — 5KB
• pbh-20241231_g1.jpg (GRAPHIC) — 65KB
• 0001295947-25-000009.txt ( ) — 8223KB
• pbh-20241231.xsd (EX-101.SCH) — 52KB
• pbh-20241231_cal.xml (EX-101.CAL) — 108KB
• pbh-20241231_def.xml (EX-101.DEF) — 198KB
• pbh-20241231_lab.xml (EX-101.LAB) — 684KB
• pbh-20241231_pre.xml (EX-101.PRE) — 455KB
• pbh-20241231_htm.xml (XML) — 1389KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Condensed Consolidated Statements of Income and Comprehensive Income for the three and nine months ended December 31, 2024 and 2023 (unaudited) 2 Condensed Consolidated Balance Sheets as of December 31, 2024 and March 31, 2024 (unaudited) 3 Condensed Consolidated Statements of Changes in Stockholders' Equity for the three and nine months ended December 31, 2024 and 2023 (unaudited) 4 Condensed Consolidated Statements of Cash Flows for the nine months ended December 31, 2024 and 2023 (unaudited) 6 Notes to Condensed Consolidated Financial Statements (unaudited) 7

Management's Discussion and Analysis of Financial Condition and Results of Operations 22

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 22

Quantitative and Qualitative Disclosures About Market Risk 34

Item 3. Quantitative and Qualitative Disclosures About Market Risk 34

Controls and Procedures 34

Item 4. Controls and Procedures 34

OTHER INFORMATION

PART II. OTHER INFORMATION

Risk Factors 34

Item 1A. Risk Factors 34

Unregistered Sales of Equity Securities and Use of Proceeds 35

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 35

Other Information 35

Item 5. Other Information 35

Exhibits 36

Item 6. Exhibits 36 Signatures 37 TRADEMARKS AND TRADE NAMES Trademarks and trade names used in this Quarterly Report on Form 10-Q are the property of Prestige Consumer Healthcare Inc. or its subsidiaries, as the case may be. We have italicized our trademarks and trade names when they appear in this Quarterly Report on Form 10-Q. -1-

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS Prestige Consumer Healthcare Inc . Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2024 2023 2024 2023 Revenues Net sales $ 290,002 $ 282,715 $ 840,385 $ 848,321 Other revenues 315 26 859 45 Total revenues 290,317 282,741 841,244 848,366 Cost of Sales Cost of sales excluding depreciation 127,360 122,794 370,098 369,772 Cost of sales depreciation 1,908 2,009 6,693 5,963 Cost of sales 129,268 124,803 376,791 375,735 Gross profit 161,049 157,938 464,453 472,631 Operating Expenses Advertising and marketing 37,945 39,466 118,719 115,799 General and administrative 26,182 26,003 81,159 79,687 Depreciation and amortization 4,960 5,637 16,228 16,869 Total operating expenses 69,087 71,106 216,106 212,355 Operating income 91,962 86,832 248,347 260,276 Other expense Interest expense, net 11,455 16,575 36,873 51,900 Other expense (income), net 353 682 1,244 ( 327 ) Total other expense, net 11,808 17,257 38,117 51,573 Income before income taxes 80,154 69,575 210,230 208,703 Provision for income taxes 19,122 16,529 45,753 48,822 Net income $ 61,032 $ 53,046 $ 164,477 $ 159,881 Earnings per share: Basic $ 1.23 $ 1.07 $ 3.31 $ 3.21 Diluted $ 1.22 $ 1.06 $ 3.28 $ 3.19 Weighted average shares outstanding: Basic 49,597 49,740 49,711 49,731 Diluted 49,993 50,125 50,085 50,134 Comprehensive income, net of tax: Currency translation adjustments ( 13,628 ) 7,465 ( 5,669 ) 3,035 Total other comprehensive (loss) income ( 13,628 ) 7,465 ( 5,669 ) 3,035 Comprehensive income $ 47,404 $ 60,511 $ 158,808 $ 162,916 See accompanying notes. -2- Prestige Consumer Healthcare Inc. Condensed Consolidated Balance Sheets ( Unaudited ) (In thousands) December 31, 2024 March 31, 2024 Assets Current assets Cash and cash equivalents $ 50,874 $ 46,469 Accounts receivable, net of allowance

View Full Filing

View this 10-Q filing on SEC EDGAR